title: Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
abstract: BACKGROUND
  The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the addition of docetaxel on patients' health-related quality of life (HRQOL) and symptoms was investigated.
  
  
  METHODS
  HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC QLQ-H&N35). The primary HRQOL scale was global HRQOL per protocol.
  
  
  RESULTS
  Compliance to HRQOL assessments was 97% at baseline, but dropped to 54% by 6 months. Data were analysed up to 6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent.
  
  
  CONCLUSIONS
  Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.
authors.affiliation: Department of Medical Oncology, Radboud University Nijmegen Medical Centre, 452, PO Box 9101, 6500 HB Nijmegen, The Netherlands. C.vanherpen@onco.umcn.nl
authors.forename: C M L
authors.initials: CM
authors.lastname: van Herpen
authors.forename: M E
authors.initials: ME
authors.lastname: Mauer
authors.forename: R
authors.initials: R
authors.lastname: Mesia
authors.forename: M
authors.initials: M
authors.lastname: Degardin
authors.forename: S
authors.initials: S
authors.lastname: Jelic
authors.forename: C
authors.initials: C
authors.lastname: Coens
authors.forename: J
authors.initials: J
authors.lastname: Betka
authors.forename: J
authors.initials: J
authors.lastname: Bernier
authors.forename: E
authors.initials: E
authors.lastname: Remenar
authors.forename: J S
authors.initials: JS
authors.lastname: Stewart
authors.forename: J H
authors.initials: JH
authors.lastname: Preiss
authors.forename: D
authors.initials: D
authors.lastname: van den Weyngaert
authors.forename: A
authors.initials: A
authors.lastname: Bottomley
authors.forename: J B
authors.initials: JB
authors.lastname: Vermorken
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D000077143:Docetaxel; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D006304:Health Status; D006801:Humans; D011788:Quality of Life; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil